Immunomedics Inc (NASDAQ:IMMU) Sentiment Change Report

September 8, 2018 - By Billy Entrekin

Immunomedics, Inc. (NASDAQ:IMMU) Logo

Sentiment for Immunomedics Inc (NASDAQ:IMMU)

Immunomedics Inc (NASDAQ:IMMU) institutional sentiment increased to 1.26 in Q1 2018. Its up 0.19, from 1.07 in 2017Q4. The ratio has improved, as 77 active investment managers started new and increased holdings, while 61 decreased and sold their equity positions in Immunomedics Inc. The active investment managers in our partner’s database now own: 117.56 million shares, up from 117.18 million shares in 2017Q4. Also, the number of active investment managers holding Immunomedics Inc in their top 10 holdings decreased from 7 to 4 for a decrease of 3. Sold All: 15 Reduced: 46 Increased: 51 New Position: 26.

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company has market cap of $4.63 billion. The firm engages in developing antibody-drug conjugate products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It currently has negative earnings. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody.

It closed at $24.78 lastly. It is down 204.95% since September 8, 2017 and is uptrending. It has outperformed by 192.38% the S&P500.

Analysts await Immunomedics, Inc. (NASDAQ:IMMU) to report earnings on November, 8. They expect $-0.26 EPS, down 62.50 % or $0.10 from last year’s $-0.16 per share. After $-0.34 actual EPS reported by Immunomedics, Inc. for the previous quarter, Wall Street now forecasts -23.53 % EPS growth.

Acuta Capital Partners Llc holds 13.96% of its portfolio in Immunomedics, Inc. for 5.85 million shares. Venbio Select Advisor Llc owns 16.94 million shares or 11.82% of their US portfolio. Moreover, Ghost Tree Capital Llc has 5.47% invested in the company for 1.85 million shares. The New York-based Iguana Healthcare Management Llc has invested 3.84% in the stock. First Light Asset Management Llc, a Minnesota-based fund reported 1.02 million shares.

Since January 1, 0001, it had 2 buys, and 0 insider sales for $18.48 million activity.

Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage

Ratings analysis reveals 100% of Immunomedics’s analysts are positive. Out of 2 Wall Street analysts rating Immunomedics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $3100 while the high is $55. The stock’s average target of $43 is 73.53% above today’s ($24.78) share price. IMMU was included in 4 notes of analysts from May 17, 2018. The stock has “Buy” rating by Wells Fargo on Thursday, May 17. FBR Capital initiated Immunomedics, Inc. (NASDAQ:IMMU) on Wednesday, June 6 with “Buy” rating. The stock has “Buy” rating by FBR Capital on Friday, August 24. The firm has “Buy” rating by Wells Fargo given on Monday, June 4.

More important recent Immunomedics, Inc. (NASDAQ:IMMU) news were published by: which released: “Immunomedics Announces Participation in Upcoming Healthcare Conferences” on August 28, 2018, also published article titled: “Immunomedics Q4 revenues down 33%”, published: “Immunomedics CFO resigns position, stays on as VP Finance” on August 23, 2018. More interesting news about Immunomedics, Inc. (NASDAQ:IMMU) was released by: and their article: “Immunomedics: Why This Biotech Could Go Crazy In 2019” with publication date: August 29, 2018.

Immunomedics, Inc. (NASDAQ:IMMU) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.